Adicet Bio/$ACET
1D1W1MYTD1Y5YMAX
About Adicet Bio
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
- Ticker
- $ACET
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 102
- Headquarters
- Boston, United States
- Website
- www.adicetbio.com
Adicet Bio Metrics
BasicAdvanced
$98M
-
-$10.52
1.59
-
Price and volume
Market cap
$98M
Beta
1.59
52-week high
$9.84
52-week low
$6.01
Average daily volume
93K
Financial strength
Current ratio
6.709
Quick ratio
6.59
Long term debt to equity
8.346
Total debt to equity
10.699
Interest coverage (TTM)
-1,280.35%
Profitability
EBITDA (TTM)
-98.121
Effective tax rate (TTM)
-0.14%
Management effectiveness
Return on assets (TTM)
-41.66%
Return on equity (TTM)
-78.08%
Valuation
Price to book
0.81
Price to tangible book (TTM)
0.81
Price to free cash flow (TTM)
-1.003
Free cash flow yield (TTM)
-99.68%
Free cash flow per share (TTM)
-9.031
Growth
Earnings per share change (TTM)
-49.49%
3-year earnings per share growth (CAGR)
-37.59%
Adicet Bio News
AllArticlesVideos
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy
MarketBeat3 weeks ago
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
Business Wire1 month ago
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference
MarketBeat3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.